ClinicalTrials.gg
Not yet recruitingNCT07745738Updated Aug 4, 2026

ICG Fluorescence Versus CO₂ Inflation-Deflation for Intersegmental Plane Identification During Thoracoscopic Segmentectomy

An interventional study of Indocyanine Green Fluorescence Imaging and Carbon Dioxide Inflation-Deflation in Pulmonary Nodule, Solitary, sponsored by Tongji Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Tongji Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Intersegmental plane identification is a critical step in thoracoscopic anatomical segmentectomy because it helps ensure adequate surgical margins while preserving healthy lung tissue. Indocyanine green (ICG) fluorescence imaging and carbon dioxide (CO₂) inflation-deflation are two techniques used to identify the intersegmental plane, but their agreement and clinical applicability have not been adequately evaluated.

This prospective paired study aims to compare the intersegmental planes identified by ICG fluorescence imaging and the CO₂ inflation-deflation method during thoracoscopic anatomical segmentectomy. In each participant, both techniques will be performed during the same operation, and the identified intersegmental planes will be compared. The findings of this study may provide evidence regarding the agreement and clinical applicability of the two methods for intersegmental plane identification.

02

Conditions studied

  • Pulmonary Nodule, Solitary
03

In context

Solitary Pulmonary Nodule

93 studies on the registry are indexed under Solitary Pulmonary Nodule; 20 are open to participants now.

This study's planned enrollment of 50 is below the median of 81 across 44 interventional studies indexed under Solitary Pulmonary Nodule.

Browse Solitary Pulmonary Nodule studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 386 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 80 years.
  2. Scheduled to undergo elective thoracoscopic anatomical segmentectomy.
  3. Preoperative thin-section chest CT with three-dimensional reconstruction available for surgical planning.
  4. Lesion considered suitable for anatomical segmentectomy by the thoracic surgery team.
  5. Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to indocyanine green (ICG).
  2. Pregnant or breastfeeding women.
  3. Severe hepatic dysfunction or other conditions contraindicating the use of ICG.
  4. Severe emphysema, bullous lung disease, diffuse pulmonary fibrosis, or other severe pulmonary parenchymal disease expected to interfere with intersegmental plane identification.
  5. Conversion to thoracotomy before completion of both intersegmental plane identification methods.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single Group

    Participants undergoing thoracoscopic anatomical segmentectomy will undergo intersegmental plane identification using indocyanine green (ICG) fluorescence imaging and carbon dioxide (CO₂) inflation-deflation during the same surgical procedure. The intersegmental planes identified by the two techniques will be compared to evaluate their clinical concordance and intraoperative performance. The final parenchymal transection line will be determined by the operating surgeon according to intraoperative clinical judgment.

    Procedure: Indocyanine Green Fluorescence Imaging · Procedure: Carbon Dioxide Inflation-Deflation

Interventions

  • ProcedureIndocyanine Green Fluorescence Imaging

    Intravenous indocyanine green (ICG) fluorescence imaging is used intraoperatively to identify the intersegmental plane during thoracoscopic anatomical segmentectomy.

  • ProcedureCarbon Dioxide Inflation-Deflation

    Carbon dioxide (CO₂) inflation-deflation is used intraoperatively to identify the intersegmental plane during thoracoscopic anatomical segmentectomy.

06

What researchers measure

Primary outcomes

  1. Clinical concordance of the intersegmental planes identified by indocyanine green fluorescence imaging and carbon dioxide inflation-deflation

    Clinical concordance between the intersegmental planes identified by the two techniques, determined by blinded assessment of de-identified intraoperative videos. Concordance is defined as Grade A or Grade B agreement; discordance is defined as Grade C.

    Time frame: Intraoperative, after both intersegmental boundaries have been identified and marked and immediately before pulmonary parenchymal division during thoracoscopic segmentectomy.

Secondary outcomes

  1. Difference in tumor-to-plane distance (Δ margin)

    Difference in the shortest distance from the tumor to the intersegmental plane identified by carbon dioxide (CO₂) inflation-deflation and indocyanine green (ICG) fluorescence imaging, measured on the resected specimen (Δ margin = CO₂ - ICG).

    Time frame: Immediately after removal of the resected specimen during the surgical procedure and before formalin fixation

  2. Time to intersegmental plane visualization

    Time from completion of the identification procedure to visualization of a clearly identifiable intersegmental plane for each technique.

    Time frame: Intraoperative, from completion of ICG injection or complete CO₂ reinflation to first visualization of the respective intersegmental boundary, before pulmonary parenchymal division during thoracoscopic segmentectomy.

  3. Technical success rate

    Proportion of procedures in which a clearly identifiable intersegmental plane is successfully visualized using each technique.

    Time frame: Intraoperative, at completion of each intersegmental plane identification technique and before pulmonary parenchymal division during thoracoscopic segmentectomy.

  4. Perioperative safety

    Perioperative adverse events related to indocyanine green (ICG) fluorescence imaging or carbon dioxide (CO₂) inflation-deflation, including allergic reactions, physiological changes, and intraoperative complications.

    Time frame: From surgery until hospital discharge

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07745738
Lead sponsor
Tongji Hospital
Responsible party
Zhang Ni (Professor, Tongji Hospital) — Principal investigator
First posted
Aug 4, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Sep 15, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Aug 4, 2026

Study contacts

Zhang Ni Zhang Ni
Contact
zhangnidoc@163.com
+8613006315393

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion